New hope for Hard-to-Treat breast cancer: drug combo trial launches

NCT ID NCT07669610

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than the drug alone. Participants will receive treatment every three weeks, and the study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab rezetecan (a drug that targets HER2 on cancer cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)
What this could lead to: If successful, this could provide a new treatment option for a hard-to-treat subtype of triple-negative breast cancer, potentially slowing disease progression.
What could go wrong: This is an early-phase 3 trial with only 140 participants, so results may not apply to all patients. The drugs can cause side effects like infusion reactions or bleeding risks, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal-like breast carcinoma breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.